Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 2/3 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Locally Advanced Bladder Cancer 1

Interventions

Sorafenib 42lenvatinib 21Fluorouracil 16atezolizumab 15Oxaliplatin 14Bevacizumab 13Doxorubicin 12Radiosurgery 11Leucovorin 11Radiofrequency Ablation 10Ethiodized Oil 10pembrolizumab 7Folfox protocol 7sintilimab 6durvalumab 6Radiotherapy 6Nivolumab 6Epirubicin 6Cisplatin 6tremelimumab 5Gemcitabine 5apatinib 4Embolization, Therapeutic 4tislelizumab 3camrelizumab 3cabozantinib 3Tenofovir 3Pharmaceutical Preparations 3Mitomycin 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Hepatocellular × Pharmaceutical Preparations × Clear all
NCT05263219 2023-06-22

DEB-TACE+HAIC vs. HAIC for Large HCC

Second Affiliated Hospital of Guangzhou Medical University

Phase 3 Unknown
230 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02973685 2023-06-12

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

Sun Yat-sen University

Phase 3 Completed
315 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03791918 2019-05-02

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Sun Yat-sen University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡